High-Fat Diet, Triglyceride Glucose Index, and Gastrointestinal Cancer: Integrative Insights From Human and Animal Studies

Why It Matters

The findings provide a readily measurable biomarker for diet‑related cancer risk, enabling earlier risk stratification and targeted prevention in clinical practice.

Key Takeaways

• TyG index strongly linked to gastrointestinal cancer
• Nonlinear risk rises below TyG 9.66 threshold
• Systemic inflammation (SII, NLR) partially mediates risk
• High‑fat diet elevates TyG and precancerous lesions in mice
• TyG uses routine labs, enabling low‑cost risk screening

Pulse Analysis

The global incidence of gastrointestinal malignancies continues to climb, driven in part by lifestyle shifts toward calorie‑dense, high‑fat diets. Excess dietary fat fuels insulin resistance, dyslipidemia, and chronic low‑grade inflammation—biological pathways that create a fertile environment for tumor initiation in the colon, stomach, liver, pancreas, and esophagus. While epidemiological links between high‑fat intake and GI cancer are well documented, clinicians have lacked a simple, reproducible metric to capture the metabolic strain imposed by such diets, limiting early‑intervention opportunities.

The triglyceride‑glucose (TyG) index, calculated from fasting triglycerides and glucose, has emerged as a cost‑effective surrogate for insulin resistance. In a recent analysis of 11,340 NHANES participants, each unit increase in TyG raised the odds of GI cancer by roughly 1.5‑fold, with the highest quartile showing a 2.6‑times greater risk. A piecewise regression identified an inflection point at TyG ≈ 9.66, below which risk escalates sharply. Mediation models further revealed that systemic immune‑inflammation markers—specifically the systemic immune‑inflammation index and neutrophil‑to‑lymphocyte ratio—account for a modest but significant portion of this association.

Because TyG relies on routine laboratory tests, it can be integrated into primary‑care workflows to flag individuals who may benefit from dietary counseling, metabolic optimization, or intensified cancer surveillance. The animal component of the study corroborates human findings, showing that high‑fat feeding raises TyG, disrupts lipid and glucose homeostasis, and produces precancerous changes across the gastrointestinal tract. Future research should pursue longitudinal cohorts to confirm causality, explore synergistic effects with gut microbiota, and test whether interventions that lower TyG—such as weight loss, low‑fat diets, or pharmacologic insulin‑sensitizers—translate into measurable reductions in GI cancer incidence.